19:11 Why Enclomiphene Is So Unpredictable
* the response is widely variable!
Enclomiphene has quietly become one of the most prescribed men's health medications in America.
It's marketed as the perfect alternative to testosterone replacement therapy (TRT): an oral medication that increases testosterone, preserves fertility, and avoids shutting down your natural hormone production.
But there's one major problem...
It never received FDA approval.
So why are thousands of men taking it every day?
As a board-certified urologist and fellowship-trained men's health specialist who has prescribed thousands of enclomiphene prescriptions, I wanted to separate the marketing from the medical evidence.
In this deep dive we cover:
Timecodes:
00:00 The Two Faces of Enclomiphene
02:39 The History of Clomid & Enclomiphene
05:07 How Enclomiphene Works
07:22 Why It Failed FDA Approva
09:24 Why Telehealth Loves Enclomiphene
11:18 The Good Side: Fertility Benefits & Preserving Sperm
13:22 The Good Side: Side Effects, Estrogen & Desmosterol
15:29 The Messy Side: Low Testosterone Treatment
16:59 IGF-1, Muscle Growth & Why Symptoms Don't Always Improve
19:11 Why Enclomiphene Is So Unpredictable
21:16 The Telehealth Problem
22:21 Who Should Actually Take Enclomiphene?
24:06 My Final Verdict
The evidence tells an interesting story. Enclomiphene reliably raises testosterone. It reliably preserves fertility. But raising a lab value and making someone actually feel better are not always the same thing.
If you're considering enclomiphene, Clomid, testosterone replacement therapy, or simply trying to understand the science behind low testosterone treatment, this video walks through the published literature, FDA history, randomized clinical trials, fertility data, side effects, and real-world clinical experience.
* the response is widely variable!
Enclomiphene has quietly become one of the most prescribed men's health medications in America.
It's marketed as the perfect alternative to testosterone replacement therapy (TRT): an oral medication that increases testosterone, preserves fertility, and avoids shutting down your natural hormone production.
But there's one major problem...
It never received FDA approval.
So why are thousands of men taking it every day?
As a board-certified urologist and fellowship-trained men's health specialist who has prescribed thousands of enclomiphene prescriptions, I wanted to separate the marketing from the medical evidence.
In this deep dive we cover:
Timecodes:
00:00 The Two Faces of Enclomiphene
02:39 The History of Clomid & Enclomiphene
05:07 How Enclomiphene Works
07:22 Why It Failed FDA Approva
09:24 Why Telehealth Loves Enclomiphene
11:18 The Good Side: Fertility Benefits & Preserving Sperm
13:22 The Good Side: Side Effects, Estrogen & Desmosterol
15:29 The Messy Side: Low Testosterone Treatment
16:59 IGF-1, Muscle Growth & Why Symptoms Don't Always Improve
19:11 Why Enclomiphene Is So Unpredictable
21:16 The Telehealth Problem
22:21 Who Should Actually Take Enclomiphene?
24:06 My Final Verdict
The evidence tells an interesting story. Enclomiphene reliably raises testosterone. It reliably preserves fertility. But raising a lab value and making someone actually feel better are not always the same thing.
If you're considering enclomiphene, Clomid, testosterone replacement therapy, or simply trying to understand the science behind low testosterone treatment, this video walks through the published literature, FDA history, randomized clinical trials, fertility data, side effects, and real-world clinical experience.
What enclomiphene is and its origin
- Enclomiphene is the trans isomer of clomiphene citrate (Clomid); clomiphene is a 2‑isomer mixture of cis (zuclomiphene) and trans (enclomiphene) forms, with marketed mix ~38% cis and 62% trans.
- Clomiphene (Clomid) was synthesized in 1956 and FDA‑approved in 1967 for ovulatory dysfunction in women; its original development and approval history explain why its isomers were later examined for male use.
Mechanism of action — why it can raise testosterone without shutting sperm production down
- Enclomiphene (and clomiphene overall) acts centrally as a selective estrogen receptor modulator (SERM) that blocks estrogen receptors in the hypothalamus and pituitary; blocking estrogen feedback increases gonadotropin‑releasing hormone (GnRH) drive, raising luteinizing hormone (LH) and follicle‑stimulating hormone (FSH).
- In men, increased LH stimulates Leydig cells to make more endogenous testosterone, while FSH (together with intratesticular testosterone) supports spermatogenesis — thus SERMs can raise serum testosterone while preserving sperm production, unlike exogenous testosterone which suppresses LH/FSH and often eliminates sperm production.
- Practical implication (mechanism → outcome): SERMs restore endogenous production (“revving your own engine”) rather than replace it; that is the core reason clinicians use enclomiphene/clomiphene when fertility preservation is important.
Regulatory and market history that shaped current use
- Repros Therapeutics developed pure enclomiphene (Androxal/Enclisix) for secondary hypogonadism and showed it raised testosterone and preserved sperm counts versus topical testosterone in trials, but regulators refused approval because trials did not convincingly show that lab increases produced clinically meaningful symptomatic benefit.
- The FDA sent a complete response letter in December 2015 citing inadequate evidence of symptom improvement and trial design issues; Repros never ran the additional required trial and the program stalled; the European agency likewise refused authorization, leaving enclomiphene without regulatory approval anywhere.
- Because no approved product exists, enclomiphene is currently obtained via compounding pharmacies and distributed largely through telehealth and compounding supply chains — a distribution route that expanded after clomiphene supply shortages and manufacturer discontinuations beginning 2019–2022.
Where the “two faces” come from — pharmacology of the isomers and side‑effects
- The cis isomer (zuclomiphene) is more estrogenic and has a much longer half‑life than enclomiphene (detectable >1 month), so taking the racemic drug (Clomid) exposes patients to sustained estrogenic activity from zuclomiphene that can produce estrogen‑related adverse effects.
- Because clomiphene is a mixture, enclomiphene as an isolated trans isomer was developed to retain anti‑estrogen central effects while reducing peripheral estrogenic stimulation — that biochemical split explains the differing clinical profiles and why many clinicians prefer enclomiphene over old‑school clomiphene in 2026.
Evidence for fertility and semen parameter effects
- Systematic reviews and meta‑analyses show clomiphene/enclomiphene improve semen parameters (sperm concentration and motility) and report mean pregnancy rates during treatment around ~17% across varied populations, though ranges were wide (0–40%).
- Enclomiphene phase II/III trials consistently showed maintained sperm concentrations versus topical testosterone, which reduced sperm counts — mechanistically and in trial results, enclomiphene preserved fertility while raising testosterone.
- Important nuance: sperm parameter improvements (counts, motility) do not equal demonstrated consistent increases in natural pregnancy rates; randomized trial meta‑analysis found no clear advantage for natural pregnancy vs placebo, so improved labs ≠ proven fertility outcomes in all settings.
- Timing caveat: testosterone commonly rises early after SERM therapy, but sperm count improvements may take much longer — one cohort found significant sperm concentration increases around 9 months, so short trials (3–4 months) can miss later benefits. Clinicians and patients must allow sufficient time before judging effectiveness for fertility purposes.
Evidence for testosterone increases and symptomatic response
- Multiple randomized trials (meta‑analysis 10 trials, 819 men) show that clomiphene/enclomiphene raise total testosterone substantially (mean difference ≈ +274 ng/dL) and increase LH and FSH, so the biochemical effect on serum testosterone is well supported.
- However, improvement in patient‑reported symptoms (libido, energy, quality of life) is less consistent. Blinded comparisons often show conventional testosterone replacement therapy (TRT) produces greater symptom improvements — particularly for libido — than clomiphene/SERM therapy, which partly explains the FDA’s rejection of Androxal for lack of demonstrated clinical benefit.
- Clinical translation point: raising the laboratory number is necessary but not sufficient — feeling better (symptom relief, sexual function, energy, quality of life) is the clinical goal, and available trials show a weaker and more variable symptom signal for SERMs versus TRT.
Safety signals, biochemical quirks, and monitoring considerations
- Desmosterol: clomiphene (especially zuclomiphene) can inhibit the final step before cholesterol, raising serum desmosterol levels; this is reported on the FDA label for clomiphene, though prolonged therapy at recommended doses reportedly does not significantly alter sterol levels in most studies. The clinical consequence (cardiovascular harm) from desmosterol elevation has not been demonstrated. Treat it as a biochemical finding of uncertain clinical significance pending more data.
- IGF‑1 and growth hormone axis: some studies (including a 2025 study of 20 hypogonadal men on clomiphene) found decreases in insulin‑like growth factor‑1 (IGF‑1) in many patients (75% in that cohort), with a few showing clinically meaningful drops; SERMs can alter hepatic signaling (via estrogen‑related pathways and Sox3) that plausibly lowers IGF‑1. However, the generalizability and clinical harm (muscle, bone, glucose) from IGF‑1 reductions are not proven and may be population‑dependent. Periodic monitoring can be reasonable in selected patients.
- Interindividual variability: genetic and hepatic metabolic differences (notably CYP2D6 variability) alter individual responses and side‑effect profiles, explaining why two men on the same dose can have very different outcomes. This hepatic metabolism variability contributes to unpredictability in both efficacy and estrogenic side effects.
- Long‑term safety gap: most trials were short (months), and there is essentially no robust long‑term safety data for men taking enclomiphene or clomiphene for years; off‑label, chronic telehealth‑driven use extends beyond trial durations and creates an evidence gap clinicians should acknowledge and monitor.
Clinical framing — who is likely to benefit and how to use enclomiphene sensibly
- Fertility indication: enclomiphene (or clomiphene historically) is an evidence‑based, rational choice for men with low sperm counts absent another correctible cause (e.g., varicocele), because it raises gonadotropins and supports spermatogenesis; in that setting many men and clinicians consider it an industry staple.
- Fertility‑preserving low‑T option: for younger men with low testosterone who wish to maintain fertility and who prefer to avoid immediate lifelong exogenous TRT, enclomiphene is a reasonable trial — it raises testosterone and preserves sperm in many patients. Clinicians commonly use it as a fertility‑sparing alternative.
- Not a universal low‑T replacement: for men whose primary goal is symptomatic improvement (libido, energy, muscle) and who have no fertility concerns, standard TRT often produces superior symptomatic benefit and predictable results; enclomiphene’s response is highly variable and should be framed as a “coin flip” for symptom relief in many patients. Expect to switch strategies if symptoms don’t improve.
- Two practical rules for patients and clinicians:
- Prioritize how you feel, not just lab numbers — if testosterone rises but symptoms do not improve, consider stepping up to alternative therapies (e.g., TRT, often combined with human chorionic gonadotropin (hCG) if fertility must be preserved).
- Choose a provider who will track symptoms and labs, and pivot treatment if enclomiphene fails rather than repeatedly prescribing the same drug hoping for a different outcome. Ensure appropriate baseline workup and follow‑up.
- Avoid old‑school racemic clomiphene in 2026: the presenter argues there is effectively no reason to prescribe generic clomiphene (the racemate) instead of isolated enclomiphene because the cis isomer doubles estrogenic risk without extra benefit. This is presented as a practice recommendation based on pharmacology and safety profile differences.
Health‑system and ethical considerations about current use via telehealth and compounding
- Economic and regulatory incentives have driven widespread telehealth prescribing of compounded enclomiphene: it avoids controlled‑substance scheduling friction, is orally delivered, preserves fertility, and is easily shipped, making it favorable for telehealth platforms even when it may not be the optimal individualized choice. This incentive structure partly explains overprescribing to marginal candidates. Clinicians and patients should be aware of that business context.
- Because enclomiphene is not FDA‑approved and is compounded, product consistency, dosing accuracy, and long‑term oversight are additional concerns not present with approved, manufactured medications; use of compounding requires careful clinician oversight.
Practical monitoring checklist (based on discussed risks and mechanisms)
- Baseline: total testosterone, LH, FSH, semen analysis (if fertility desired), estradiol, liver panel, lipid panel, and relevant pituitary imaging if indicated by history.
- Follow‑up: symptom tracking (libido, energy, mood), serial testosterone/LH/FSH, periodic semen analyses (if fertility goal), and consider checking IGF‑1 in selected patients or if clinical concern arises; monitor for estrogenic side effects (mood changes, nipple sensitivity) and counsel about variable response timing (sperm improvements may take ~9 months).
- Switch criteria: if testosterone rises but symptoms fail to improve within a reasonable trial period and patient priorities require symptom relief, discuss transition to TRT (with fertility‑protecting strategies like hCG if applicable).
Bottom line, evidence‑grounded takeaways
- Biochemistry: enclomiphene reliably raises serum testosterone and gonadotropins by blocking central estrogen receptors, and preserves spermatogenesis compared with exogenous TRT — the pharmacologic rationale is strong and supported by trials.
- Fertility use: it is a genuinely useful fertility‑adjacent drug that improves semen parameters and preserves fertility; however, improved semen metrics do not universally equal higher natural pregnancy rates, and conceiving may require longer treatment and patience.
- Symptom effectiveness: raising testosterone labs does not guarantee symptom relief; clinical trials and regulatory review highlight weak or inconsistent symptom benefit versus TRT, and individual responses are highly variable. Expect a trial‑and‑monitor approach and be ready to change course if symptoms do not improve.
- Safety/uncertainty: short‑term safety appears acceptable, but long‑term safety data are lacking; biochemical quirks (desmosterol, IGF‑1 changes) exist but lack definitive evidence of long‑term harm — monitor and counsel patients about these uncertainties.
- Clinical recommendation summary: use enclomiphene preferentially when fertility preservation is a priority or when a patient wants to try avoiding lifelong TRT, but recognize variable symptomatic outcomes and choose clinicians who will monitor, interpret labs in context, and escalate to alternative therapies when needed. Avoid prescribing racemic clomiphene when pure enclomiphene is accessible because of higher estrogenic risk from zuclomiphene.
Last edited by a moderator:
